Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Circulation

• Publication date

  2007-07-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.106.666016PMID 17576868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease.

  2005cited by this paper
• Ventricular remodeling in heart failure and the effect of beta-blockade.

  2004cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction

  2004cited by this paper
• Metoprolol CR/XL Improves Systolic and Diastolic Left Ventricular Function in Patients with Chronic Heart Failure

  2004cited by this paper
• Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.

  2003cited by this paper
• Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community

  2003cited by this paper
• Ventricular remodeling in heart failure: a credible surrogate endpoint.

  2003cited by this paper
• Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

  2003cited by this paper
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study

  2002cited by this paper
• Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

  2001cited by this paper
• World Wide Web at:

  2001cited by this paper
• Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

  2000cited by this paper
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study.

  2000cited by this paper
• Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.

  2000cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.

  1999cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease

  1997cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

  1997cited by this paper
• Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

  1996cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators.

  1995cited by this paper
• Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction

  1995cited by this paper
• Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

  1995cited by this paper
• Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators.

  1994cited by this paper
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

  1992cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).

  1990cited by this paper
• Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method

  1977cited by this paper

• Valvular heart failure: evolving pharmacological approaches.

  2026cites this paper
• The Prognostic Implications of Change in LVEDP during TAVI

  2025cites this paper
• Cardioprotective Mechanisms of Beta-Blockers in Myocardial Ischemia and Reperfusion: From Molecular Targets to Clinical Implications

  2025cites this paper
• Prognostic Implications of Guideline-Directed Medical Therapy for Heart Failure in Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis

  2025cites this paper
• JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.

  2025cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.

  2025cites this paper
• JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.

  2025cites this paper
• mTORC1 hyperactivation and resultant suppression of macroautophagy contribute to the induction of cardiomyocyte necroptosis by catecholamine surges

  2024cites this paper
• Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta‐analysis

  2024cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

  2024cites this paper
• Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine

  2024cites this paper
• Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review

  2024cites this paper
• Dilated Cardiomyopathy, De Novo Heart Failure, and Cardiogenic Shock With End-Organ Failure in a Patient With No Cardiac History Following a Trial of Amitriptyline

  2024cites this paper
• Guía latinoamericana de recomendaciones al egreso de un síndrome coronario agudo

  2024cites this paper
• Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis

  2024cites this paper
• Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial

  2024cites this paper
• Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week.

  2024cites this paper
• Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction

  2024cites this paper
• Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure

  2023cites this paper
• Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential

  2023cites this paper
• Blood pressure in heart failure management and prevention

  2023cites this paper
• Systematic investigation of the multi-scale mechanisms of herbal medicine on treating ventricular remodeling: Theoretical and experimental studies.

  2023cites this paper
• Artificial intelligence-enabled electrocardiographic screening for left ventricular systolic dysfunction and mortality risk prediction

  2023cites this paper
• Pharmacological Therapy Optimization for Heart Failure: A Practical Guide for the Internist.

  2023cites this paper
• Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions

  2023cites this paper
• A 20-year population study of peripartum cardiomyopathy

  2023cites this paper
• Hypertension and Heart Failure

  2023cites this paper
• Beta Blockade Prevents Cardiac Morphological and Molecular Remodelling in Experimental Uremia

  2023cites this paper
• 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

  2023cites this paper
• Accelerated and personalized therapy for heart failure with reduced ejection fraction.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy

  2022cites this paper
• Left ventricular volume change and long-term outcomes in ischaemic cardiomyopathy with or without surgical revascularisation: A post-hoc analysis of a randomised controlled trial

  2022cites this paper
• Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy

  2022cites this paper
• Medical Therapy for Functional Mitral Regurgitation

  2022cites this paper
• Recovery From Left Ventricular Dysfunction

  2022influential citation
• Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

  2022cites this paper
• Hypertension and Heart Failure: Prevention, Targets, and Treatment.

  2022cites this paper
• Left ventricular reverse remodelling and its predictors in non‐ischaemic cardiomyopathy

  2022cites this paper
• Role of CCR2-Positive Macrophages in Pathological Ventricular Remodelling

  2022cites this paper
• The 'diamond' approach to personalized drug treatment of heart failure with reduced ejection fraction.

  2021cites this paper
• Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

  2021cites this paper
• The Effectiveness of a Deep Learning Model to Detect Left Ventricular Systolic Dysfunction from Electrocardiograms.

  2021cites this paper
• Clinical impact of echocardiography parameters and molecular biomarkers in heart failure: Correlation of ACE2 and MCP-1 polymorphisms with echocardiography parameters: A comparative study.

  2021cites this paper
• Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction

  2021influential citation
• Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction

  2020cites this paper
• Short-Term Ventricular Structural Changes Following Left Ventricular Assist Device Implantation.

  2020cites this paper
• Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan

  2020cites this paper
• VHRM_A_197291 41..51

  2020cites this paper
• Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.

  2020cites this paper
• Second Hits in Dilated Cardiomyopathy

  2020cites this paper
• Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

  2020cites this paper
• (cid:1) -Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction

  2020cites this paper
• Hypertension and Heart Failure: Prevention, Targets, and Treatment.

  2020cites this paper
• Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure

  2019cites this paper
• Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy.

  2019cites this paper
• Diagnosis and Prevention of Hypertensive Heart Failure.

  2019cites this paper
• Role of beta-blockers in cardiovascular disease in 2019.

  2019cites this paper
• Epidemiology of Heart Failure

  2019cites this paper
• Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019

  2019cites this paper
• OBSOLETE: Neurohormonal Blockade

  2018cites this paper
• Metoprolol in the treatment of cardiovascular disease: a critical reappraisal

  2018cites this paper
• Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline.

  2018cites this paper
• Mechanical Unloading in Heart Failure.

  2018cites this paper
• Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

  2018cites this paper
• &bgr;-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial

  2018cites this paper
• Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling

  2018cites this paper
• Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure.

  2018cites this paper
• Left ventricular reverse remodelling predicts long‐term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry

  2018cites this paper
• University of Groningen Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer Sieswerda,

  2018cites this paper
• Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block.

  2018cites this paper
• Stroke and the heart : a focus on atrial fibrillation and heart failure

  2017cites this paper
• Declining Risk of Sudden Death in Heart Failure.

  2017cites this paper
• Parachute-Implantation bei schwerer ischämischer Herzinsuffizienz

  2017cites this paper
• [Parachute Implantation in Severe Ischemic Cardiomyopathy].

  2017cites this paper
• Declining Risk of Sudden Death in Heart Failure

  2017cites this paper
• A Treatment Approach for Patients With Chronic Systolic Heart Failure.

  2016cites this paper
• Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

  2016cites this paper
• Impact of Beta Blockers on Left Ventricular Reverse Remodeling Following Primary Coronary Intervention for ST-elevation Myocardial Infarction.

  2016cites this paper
• Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis.

  2016cites this paper
• Contributory risk and Management of Comorbidities of Hypertension, obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure

  2016cites this paper
• Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation

  2016cites this paper
• Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?

  2016cites this paper
• The Future of Heart Failure Diagnosis, Therapy, and Management.

  2016cites this paper
• [The Impact of Asymptomatic Left Ventricular Dilatation on the Course of Anterior Myocardial Infarction.]

  2016cites this paper
• Cardiac Outcomes in Survivors of Pediatric and Adult Cancers.

  2016cites this paper
• Reverse Remodeling in Systolic Heart Failure

  2015cites this paper
• Penyekat Beta sebagai Terapi Anti-Remodeling pada Gagal Jantung

  2015cites this paper
• Effects of Bisoprolol and Carvedilol on Left Ventricular Remodeling in Patients with Chronic Heart Failure

  2015cites this paper
• The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.

  2015cites this paper
• Matters of the heart: genetic and molecular characterisation of cardiomyopathies

  2015cites this paper
• Percutaneous left ventricular restoration.

  2015cites this paper
• Anthracycline-Induced Cardiomyopathy in Adults.

  2015cites this paper
• A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms

  2015cites this paper
• Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010

  2015cites this paper
• Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?

  2014cites this paper
• It's time to study cardiac magnetic resonance imaging as a strategic tool in nonischemic cardiomyopathy.

  2014cites this paper
• Management of ACCF/AHA Stage A and B patients.

  2014cites this paper
• GENETIC CAUSES OF DILATED CARDIOMYOPATHY.

  2014cites this paper